<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854746</url>
  </required_header>
  <id_info>
    <org_study_id>VXA-NVV-104</org_study_id>
    <nct_id>NCT04854746</nct_id>
  </id_info>
  <brief_title>Ph 1b: Safety &amp; Immunogenicity of Ad5 Based Oral Norovirus Vaccine</brief_title>
  <acronym>VXA-NVV-104</acronym>
  <official_title>A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Oral Norovirus Vaccine Expressing GI.1 VP1 Administered Orally to Health Stable Older Adult Volunteers 55-80 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b, multicenter, randomized, double-blind, placebo-controlled study to determine the&#xD;
      safety and immunogenicity of an adenoviral-vector based oral norovirus vaccine expressing&#xD;
      GI.1 VP1 administered orally to healthy older adult volunteers 55-80 years of age. The study&#xD;
      is designed to assess the safety, tolerability, immunogenicity, and efficacy of 3 dose levels&#xD;
      of vaccine with a 2-dose vaccination schedule (4 weeks apart) in healthy older adults (55 to&#xD;
      80 years old)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1b, multicenter, randomized, double-blind, placebo-controlled study to determine the&#xD;
      safety and immunogenicity of an adenoviral-vector based oral norovirus vaccine expressing&#xD;
      GI.1 VP1 administered orally to healthy older adult volunteers 55-80 years of age. The study&#xD;
      is designed to assess the safety, tolerability, immunogenicity, and efficacy of 3 dose levels&#xD;
      of vaccine with a 2-dose vaccination schedule (4 weeks apart) in healthy older adults (55 to&#xD;
      80 years old).&#xD;
&#xD;
      Subjects will we randomized in the study utilizing an age and dose escalation schedule. A&#xD;
      Safety Monitoring Committee will provide oversight of the trial throughout the duration of&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Solicited Adverse Events</measure>
    <time_frame>Day 1 (Vaccination) to 7 days post vaccination</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Unsolicited Adverse Events</measure>
    <time_frame>Day 1 (Vaccination) to 28 days post vaccination</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VP1 specific IgA ASC</measure>
    <time_frame>Day 1 (Vaccination) to 7 days post vaccination</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norovirus GI.1 histo-blood group antigen GBGA blocking antibodies (BT50)</measure>
    <time_frame>Day 1 (Vaccination) to 7 days post vaccination</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VP1 specific serum IgG</measure>
    <time_frame>Day 1 (Vaccination) to 7 days post vaccination</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Norovirus Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Low Dose Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 High Dose Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Low Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching in number and appearance to active vaccine doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 High Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching in number and appearance to active vaccine doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Medium Dose Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 3x10Log11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Medium Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching in number and appearance to active vaccine doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-GI.1.NN</intervention_name>
    <description>GI.1 oral vaccine tablet</description>
    <arm_group_label>Cohort 1 Low Dose Active</arm_group_label>
    <arm_group_label>Cohort 2 Medium Dose Active</arm_group_label>
    <arm_group_label>Cohort 3 High Dose Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Tablets matching in number and appearance to active vaccine tablets</description>
    <arm_group_label>Cohort 1 Low Dose Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Medium Dose Placebo</arm_group_label>
    <arm_group_label>Cohort 3 High Dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        To be eligible for this study, participants must meet all the following:&#xD;
&#xD;
        Age&#xD;
&#xD;
          1. 55 to 80 years old inclusive at the time of signing the Informed Consent Form (ICF).&#xD;
&#xD;
             Type of Participants&#xD;
&#xD;
          2. In stable and good general health, without significant medical illness, based on&#xD;
             medical history, physical examination and vital signs at screening&#xD;
&#xD;
          3. Safety laboratory values within the following range criteria at screening:&#xD;
&#xD;
               1. Laboratory value of &lt; grade 1 elevation from normal or decrease from normal with&#xD;
                  no clinical significance (NCS) for alkaline phosphatase (ALP), alanine&#xD;
                  aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin,&#xD;
&#xD;
               2. Laboratory value of &lt; grade 1 from normal with no NCS for:&#xD;
&#xD;
                    -  decreased: albumin, magnesium, total protein and phosphorous&#xD;
&#xD;
                    -  elevated: amylase, BUN, CPK and creatine and;&#xD;
&#xD;
                    -  elevated or decreased: calcium, glucose, potassium and sodium;&#xD;
&#xD;
          4. Body mass index (BMI) between 17 and 35 kg/m2 at screening&#xD;
&#xD;
          5. Available for all planned visits and phone calls, and willing to complete all&#xD;
             protocol- defined procedures and assessments (including ability and willingness to&#xD;
             swallow multiple small enteric-coated tablets per study dose).&#xD;
&#xD;
             Gender and Reproductive Considerations&#xD;
&#xD;
          6. Male or female participants Female participants must provide a negative pregnancy test&#xD;
             at screening and baseline or be at least one year post-menopausal or surgically&#xD;
             sterile. Female participants of childbearing potential must be willing to use a&#xD;
             reliable oral, implantable, transdermal or injectable contraceptive for 30 days prior&#xD;
             to and until 60 days post last study drug administration. The form of contraception&#xD;
             must be approved by the Investigator Contraception use by men should be consistent&#xD;
             with local regulations regarding the methods of contraception for participants in&#xD;
             clinical studies.&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          7. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in this protocol.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        The participants must be excluded from participating in the study if they meet any of the&#xD;
        following:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic)&#xD;
             including institution of new medical/surgical treatment or significant dose alteration&#xD;
             for uncontrolled symptoms or drug toxicity within 3 months of screening and&#xD;
             reconfirmed at baseline&#xD;
&#xD;
          2. Cancer, or treatment for cancer treatment, within past 3 years (excluding basal cell&#xD;
             carcinoma or squamous cell carcinoma)&#xD;
&#xD;
          3. Presence of immunosuppression or medical condition possibly associated with impaired&#xD;
             immune responsiveness, including diabetes mellitus&#xD;
&#xD;
          4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal&#xD;
             condition that could affect the distribution/safety evaluation of an orally&#xD;
             administered vaccine targeting the mucosa of the small intestine.&#xD;
&#xD;
             Such conditions may include but are not limited to:&#xD;
&#xD;
               1. Esophageal Motility Disorder&#xD;
&#xD;
               2. Malignancy&#xD;
&#xD;
               3. Malabsorption&#xD;
&#xD;
               4. Pancreaticobiliary disorders&#xD;
&#xD;
               5. Irritable bowel syndrome&#xD;
&#xD;
               6. Inflammatory Bowel Disease&#xD;
&#xD;
               7. Surgical Resection&#xD;
&#xD;
               8. GERD&#xD;
&#xD;
               9. Hiatal Hernia&#xD;
&#xD;
              10. Peptic Ulcer (History of cholecystectomy is not exclusionary)&#xD;
&#xD;
          5. History of any form of angioedema&#xD;
&#xD;
          6. History of serious reactions to vaccination such as anaphylaxis, respiratory problems,&#xD;
             hives or abdominal pain&#xD;
&#xD;
          7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that&#xD;
             could make blood draws problematic&#xD;
&#xD;
          8. Any condition that resulted in the absence or removal of the spleen&#xD;
&#xD;
          9. Acute disease within 72 hours prior to vaccination defined as the presence of a&#xD;
             moderate or severe illness (as determined by the Investigator through medical history&#xD;
             and physical exam). (Assessment may be repeated during screening period.)&#xD;
&#xD;
         10. Presence of a fever ≥ 38oC measured orally at baseline (Assessment may be repeated&#xD;
             during screening period)&#xD;
&#xD;
         11. Any significant hospitalization within the last year which in the opinion of the&#xD;
             investigator or sponsor could interfere with study participation.&#xD;
&#xD;
         12. Any of the following history or conditions that may lead to higher risk of clotting&#xD;
             events and/or thrombocytopenia:&#xD;
&#xD;
               1. Family or personal history of bleeding or thrombosis&#xD;
&#xD;
               2. History of heparin-related thrombotic events, and/or receiving heparin treatments&#xD;
&#xD;
               3. History of autoimmune or inflammatory disease&#xD;
&#xD;
               4. Presence of any of the following conditions known to increase risk of thrombosis&#xD;
                  within 6 months prior to screening:&#xD;
&#xD;
                    -  Recent surgery other than removal/biopsy of cutaneous lesions&#xD;
&#xD;
                    -  Immobility (confined to bed or wheelchair for 3 or more successive days)&#xD;
&#xD;
                    -  Head trauma with loss of consciousness or documented brain injury&#xD;
&#xD;
                    -  Receipt of anticoagulants for prophylaxis of thrombosis&#xD;
&#xD;
                    -  Recent clinically significant infection&#xD;
&#xD;
         13. Any other condition that in the clinical judgment of the investigator would jeopardize&#xD;
             the safety or rights of a participant taking in the study, would render the&#xD;
             participant unable to comply with the protocol or would interfere with the evaluation&#xD;
             of the study endpoints Diagnostic Assessments&#xD;
&#xD;
         14. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or&#xD;
             hepatitis C virus (HCV) tests at the screening visit&#xD;
&#xD;
         15. Stool sample with occult blood at screening&#xD;
&#xD;
         16. Positive urine drug screen for drugs of abuse at screening (postive test for marijuana&#xD;
             is not exclusionary; however concurrent use of marijuana during the study Active&#xD;
             period through Day 57 is prohibited)&#xD;
&#xD;
         17. Positive breath or urine alcohol test at screening and baseline Prior/Concurrent&#xD;
             Therapy&#xD;
&#xD;
         18. Receipt of a licensed vaccine (including any COVID-19 vaccines under Emergency Use&#xD;
             Authorization) within 14 days prior to baseline vaccination or planned administration&#xD;
             during the study active period (Day 57)&#xD;
&#xD;
         19. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days&#xD;
             prior to study drug administration or planned use during the active study period (Day&#xD;
             57)&#xD;
&#xD;
         20. Use of medications known to affect the immune function (e.g., systemic corticosteroids&#xD;
             and others) within 2 weeks before study drug administration or planned use during the&#xD;
             active study period (Day 57)&#xD;
&#xD;
         21. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug&#xD;
             administration or planned use during the active study period (Day 57)&#xD;
&#xD;
         22. Administration of any investigational vaccine, drug or device within 8 weeks preceding&#xD;
             study drug administration, or planned use within the duration of the study Other&#xD;
             Exclusions&#xD;
&#xD;
         23. Donation or use of blood or blood products within 30 days prior to study drug&#xD;
             administration or planned donation during the active study period (Day 57)&#xD;
&#xD;
         24. History of drug, alcohol or chemical abuse within 1 year of screening&#xD;
&#xD;
         25. History of hypersensitivity or allergic reaction to any component of the&#xD;
             investigational vaccine, including but not limited to fish gelatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liebowitz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vaxart, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaily J Garg</last_name>
    <phone>650-521-4496</phone>
    <email>sgarg@vaxart.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Hummel</last_name>
    <phone>415-407-8331</phone>
    <email>chummel@vaxart.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Smith</last_name>
      <email>brett.smith@wcct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cotungo</last_name>
      <email>michaelcotungo@benchmarkresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Chu</last_name>
      <email>lawrencechu@benchmarkresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>norovirus, oral vaccine, elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caliciviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study results will be summarized and presented by treatment arm comparisons. Individual subject data will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

